BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Okines A, Verheij M, Allum W, Cunningham D, Cervantes A; ESMO Guidelines Working Group. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v50-v54. [PMID: 20555102 DOI: 10.1093/annonc/mdq164] [Cited by in Crossref: 195] [Cited by in F6Publishing: 203] [Article Influence: 17.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu T, Ye YW, Zhu AL, Yang Z, Fu Y, Wei CQ, Liu Q, Zhao CL, Wang GJ, Zhang XF. Hyperthermia combined with 5-fluorouracil promoted apoptosis and enhanced thermotolerance in human gastric cancer cell line SGC-7901. Onco Targets Ther. 2015;8:1265-1270. [PMID: 26064061 DOI: 10.2147/ott.s78514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
2 You YH, Kim YM, Ahn DH. Beginner Surgeon's Initial Experience with Distal Subtotal Gastrectomy for Gastric Cancer Using a Minimally Invasive Approach. J Gastric Cancer 2015;15:270-7. [PMID: 26819806 DOI: 10.5230/jgc.2015.15.4.270] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
3 Kairouani M, Perrin J, Dietemann-Barabinot A, Diab R, Ruck S. Cutaneous metastasis revealing a relapse of gastric linitis: Another case. Int J Surg Case Rep 2013;4:185-7. [PMID: 23276763 DOI: 10.1016/j.ijscr.2012.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
4 Wang C, Bao C, Liang S, Zhang L, Fu H, Wang Y, Wang K, Li C, Deng M, Liao Q, Ni J, Cui D. HAI-178 antibody-conjugated fluorescent magnetic nanoparticles for targeted imaging and simultaneous therapy of gastric cancer. Nanoscale Res Lett 2014;9:274. [PMID: 24948895 DOI: 10.1186/1556-276X-9-274] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
5 Bencivenga M, Palla I, Scorsone L, Bortolami A, Mengardo V, Pavarana M, Turchetti G, de Manzoni G. Clinical pathways in gastric cancer care. Updates Surg 2018;70:279-91. [PMID: 29923079 DOI: 10.1007/s13304-018-0544-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Yarema R, de Manzoni G, Fetsych T, Ohorchak M, Pliatsko M, Bencivenga M. On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer. World J Gastrointest Oncol 2016; 8(6): 489-497 [PMID: 27326318 DOI: 10.4251/wjgo.v8.i6.489] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
7 Goto H, Tokunaga M, Sugisawa N, Tanizawa Y, Bando E, Kawamura T, Niihara M, Tsubosa Y, Terashima M. Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction. Gastric Cancer. 2013;16:590-595. [PMID: 23179369 DOI: 10.1007/s10120-012-0214-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
8 Baba H, Kanda M, Sawaki K, Umeda S, Miwa T, Shimizu D, Tanaka C, Kobayashi D, Fujiwara M, Kodera Y, Fujii T. PRAME as a Potential Biomarker for Liver Metastasis of Gastric Cancer. Ann Surg Oncol 2020;27:2071-80. [DOI: 10.1245/s10434-019-07985-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ye BW, Lee KC, Hsieh YC, Li CP, Chao Y, Hou MC, Lin HC. Self-Expandable Metallic Stent Placement in Malignant Gastric Outlet Obstruction: A Comparison Between 2 Brands of Stents. Medicine (Baltimore) 2015;94:e1208. [PMID: 26200641 DOI: 10.1097/MD.0000000000001208] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
10 Bang Y, Kim Y, Yang H, Chung HC, Park Y, Lee KH, Lee K, Kim YH, Noh S, Cho JY, Mok YJ, Kim YH, Ji J, Yeh T, Button P, Sirzén F, Noh SH. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. The Lancet 2012;379:315-21. [DOI: 10.1016/s0140-6736(11)61873-4] [Cited by in Crossref: 866] [Cited by in F6Publishing: 527] [Article Influence: 96.2] [Reference Citation Analysis]
11 Sanford M. Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. Drugs. 2013;73:1605-1615. [PMID: 24057416 DOI: 10.1007/s40265-013-0119-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
12 Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Ann Surg Oncol 2015;22:905-14. [DOI: 10.1245/s10434-015-4617-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
13 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941.ecollection] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Chen QY, Zhong Q, Zhou JF, Qiu XT, Dang XY, Cai LS, Su GQ, Xu DB, Lin GT, Guo KQ, Liu ZY, Chen QX, Li P, Li TW, Xie JW, Lin SM, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Zheng CH, Lin W, He QL, Huang CM. Conditional survival and recurrence of remnant gastric cancer after surgical resection: A multi-institutional study. Cancer Sci 2020;111:502-12. [PMID: 31710406 DOI: 10.1111/cas.14231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang JB, Zhong Q, Wang W, Desiderio J, Chen S, Liu ZY, Chen QY, Li P, Xie JW, Liu FQ, Zheng CH, Peng JS, Zhou ZW, Parisi A, Huang CM. Postoperative dynamic survival of gastric cancer patients: A multi-institutional, international analysis of 22 265 patients. J Surg Oncol 2019;120:685-97. [PMID: 31317558 DOI: 10.1002/jso.25637] [Reference Citation Analysis]
16 Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 2015;18:1-10. [PMID: 24638977 DOI: 10.1007/s10120-014-0356-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
17 Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E, Ciardiello F, De Vita F. Treatment of gastric cancer. World J Gastroenterol 2014; 20(7): 1635-1649 [PMID: 24587643 DOI: 10.3748/wjg.v20.i7.1635] [Cited by in CrossRef: 323] [Cited by in F6Publishing: 313] [Article Influence: 46.1] [Reference Citation Analysis]
18 Aoyama T, Yoshikawa T. Adjuvant therapy for locally advanced gastric cancer. Surg Today. 2017;47:1295-1302. [PMID: 28251375 DOI: 10.1007/s00595-017-1493-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
19 Roviello F, Caruso S, Neri A, Marrelli D. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol. 2013;39:1309-1316. [PMID: 24183797 DOI: 10.1016/j.ejso.2013.10.010] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
20 Kulig J, Kołodziejczyk P, Kulig P, Legutko J. Targeted therapy for gastric cancer--current status. J Oncol Pharm Pract 2013;19:75-81. [PMID: 22711713 DOI: 10.1177/1078155212449030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
21 Owen GI, Pinto MP, Retamal IN, Fernádez MF, Cisternas B, Mondaca S, Sanchez C, Galindo H, Nervi B, Ibañez C, Acevedo F, Madrid J, Peña J, Bravo ML, Maturana MJ, Cordova-Delgado M, Romero D, de la Jara N, Torres J, Rodriguez-Fernandez M, Espinoza M, Balmaceda C, Freire M, Gárate-Calderón V, Crovari F, Jimenez-Fonseca P, Carmona-Bayonas A, Zwenger A, Armisen R, Corvalan AH, Garrido M. Chilean Gastric Cancer Task Force: A study protocol to obtain a clinical and molecular classification of a cohort of gastric cancer patients. Medicine (Baltimore) 2018;97:e0419. [PMID: 29668600 DOI: 10.1097/MD.0000000000010419] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
22 Uslu A, Zengel B, İlhan E, Aykas A, Şimşek C, Üreyen O, Duran A, Okut G. Survival outcomes after D1 and D2 lymphadenectomy with R0 resection in stage II-III gastric cancer: Longitudinal follow-up in a single center. Turk J Surg 2018;34:125-30. [PMID: 30023977 DOI: 10.5152/turkjsurg.2018.3846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
23 Montori G, Coccolini F, Ceresoli M, Catena F, Colaianni N, Poletti E, Ansaloni L. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol. 2014;2014:912418. [PMID: 24693422 DOI: 10.1155/2014/912418] [Cited by in Crossref: 22] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
24 Liu N, Liu X, Zhou N, Wu Q, Zhou L, Li Q. Gene expression profiling and bioinformatics analysis of gastric carcinoma. Exp Mol Pathol 2014;96:361-6. [PMID: 24589858 DOI: 10.1016/j.yexmp.2014.02.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
25 Choi YY, An JY, Guner A, Kang DR, Cho I, Kwon IG, Shin HB, Hyung WJ, Noh SH. Skip lymph node metastasis in gastric cancer: is it skipping or skipped? Gastric Cancer 2016;19:206-15. [PMID: 25708370 DOI: 10.1007/s10120-015-0472-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
26 Fan M, Hu W, Zhang Z. Chemoradiation for gastric cancer: controversies, updates and novel techniques. Br J Radiol 2015;88:20150027. [PMID: 25827208 DOI: 10.1259/bjr.20150027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
27 Rodríguez-Sanjuán JC, Gómez-Ruiz M, Trugeda-Carrera S, Manuel-Palazuelos C, López-Useros A, Gómez-Fleitas M. Laparoscopic and robot-assisted laparoscopic digestive surgery: Present and future directions. World J Gastroenterol 2016; 22(6): 1975-2004 [PMID: 26877605 DOI: 10.3748/wjg.v22.i6.1975] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 21] [Article Influence: 6.2] [Reference Citation Analysis]
28 Beeharry MK, Liu WT, Yao XX, Yan M, Zhu ZG. A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol 2016;1:77. [PMID: 28138643 DOI: 10.21037/tgh.2016.08.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
29 Nowara E, Boratyn-Nowicka A, Polakiewicz-Gilowska A, Drosik A, Kustra M, Huszno J. Chemotherapy for gastric cancer patients - time for personalization in medicine? Contemp Oncol (Pozn) 2012;16:86-9. [PMID: 23788860 DOI: 10.5114/wo.2012.27342] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Kim YH, Muro K, Yasui H, Chen JS, Ryu MH, Park SH, Chu KM, Choo SP, Sanchez T, DelaCruz C, Mukhopadhyay P, Lainas I, Li CP. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemother Pharmacol 2012;70:583-90. [PMID: 22886073 DOI: 10.1007/s00280-012-1943-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
31 Verlato G, Giacopuzzi S, Bencivenga M, Morgagni P, Manzoni GD. Problems faced by evidence-based medicine in evaluating lymphadenectomy for gastric cancer. World J Gastroenterol 2014; 20(36): 12883-12891 [PMID: 25278685 DOI: 10.3748/wjg.v20.i36.12883] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
32 Fukagawa T, Katai H, Mizusawa J, Nakamura K, Sano T, Terashima M, Ito S, Yoshikawa T, Fukushima N, Kawachi Y, Kinoshita T, Kimura Y, Yabusaki H, Nishida Y, Iwasaki Y, Lee SW, Yasuda T, Sasako M;  Stomach Cancer Study Group of the Japan Clinical Oncology Group. A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer. 2018;21:68-73. [PMID: 28194522 DOI: 10.1007/s10120-017-0701-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 11.8] [Reference Citation Analysis]
33 Yoshikawa T, Sasako M. Adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nat Rev Clin Oncol 2012;9:192-4. [DOI: 10.1038/nrclinonc.2012.23] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
34 Shin CI, Kim SH. Normal and Abnormal Postoperative Imaging Findings after Gastric Oncologic and Bariatric Surgery. Korean J Radiol 2020;21:793-811. [PMID: 32524781 DOI: 10.3348/kjr.2019.0822] [Reference Citation Analysis]
35 Chong CS, Ng CW, Shabbir A, Kono K, So JBY. Computed tomography of the thorax for gastric cancer staging: is it necessary? Scand J Surg 2015;104:244-7. [DOI: 10.1177/1457496915571400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Ford HER, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. The Lancet Oncology 2014;15:78-86. [DOI: 10.1016/s1470-2045(13)70549-7] [Cited by in Crossref: 326] [Cited by in F6Publishing: 180] [Article Influence: 46.6] [Reference Citation Analysis]
37 Shrikhande SV, Sirohi B, Barreto SG, Chacko RT, Parikh PM, Pautu J, Arya S, Patil P, Chilukuri SC, Ganesh B, Kaur T, Shukla D, Rath GS. Indian Council of Medical Research consensus document for the management of gastric cancer. Indian J Med Paediatr Oncol 2014;35:239-43. [PMID: 25538398 DOI: 10.4103/0971-5851.144970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
38 Yin L, Xu G, Zhu Y, Wang Y. Expression of miR-23a and miR-135 and tumor markers in gastric cancer patients and the significance in diagnosis. Oncol Lett 2019;18:5853-8. [PMID: 31788058 DOI: 10.3892/ol.2019.10943] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Sasaki K, Onodera S, Otsuka K, Satomura H, Kurayama E, Kubo T, Takahashi M, Ito J, Nakajima M, Yamaguchi S, Miyachi K, Kato H. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Med Oncol 2017;34:139. [PMID: 28707042 DOI: 10.1007/s12032-017-0997-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
40 Dikken JL, Coit DG, Baser RE, Gönen M, Goodman KA, Brennan MF, Jansen EP, Boot H, van de Velde CJ, Cats A, Verheij M. Performance of a nomogram predicting disease-specific survival after an R0 resection for gastric cancer in patients receiving postoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 2014;88:624-9. [PMID: 24411620 DOI: 10.1016/j.ijrobp.2013.11.213] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
41 Gómez-martín C, Salazar R, Montagut C, Gil-martín M, Núñez JA, Puig M, Lin X, Khosravan R, Tursi JM, Lechuga MJ, Bellmunt J. A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. Invest New Drugs 2013;31:390-8. [DOI: 10.1007/s10637-012-9830-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
42 Seyfried F, von Rahden BH, Miras AD, Gasser M, Maeder U, Kunzmann V, Germer CT, Pelz J, Kerscher AG. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015;15:73. [PMID: 25879885 DOI: 10.1186/s12885-015-1081-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
43 Berlth F, Bollschweiler E, Drebber U, Hoelscher AH, Moenig S. Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value. World J Gastroenterol 2014; 20(19): 5679-5684 [PMID: 24914328 DOI: 10.3748/wjg.v20.i19.5679] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 63] [Article Influence: 10.1] [Reference Citation Analysis]
44 Lu J, Zheng ZF, Zhou JF, Xu BB, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Chen QY, Truty MJ, He QL, Huang CM. A novel prognosis prediction model after completion gastrectomy for remnant gastric cancer: Development and validation using international multicenter databases. Surgery 2019;166:314-21. [PMID: 31221436 DOI: 10.1016/j.surg.2019.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Cordero-García E, Ramos-Esquivel A, Alpízar-Alpízar W. Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study. J Gastrointest Oncol 2019;10:523-8. [PMID: 31183203 DOI: 10.21037/jgo.2019.01.18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Kanaji S, Suzuki S, Matsuda Y, Hasegawa H, Yamamoto M, Yamashita K, Oshikiri T, Matsuda T, Nakamura T, Sumi Y, Kakeji Y. Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer. Ann Gastroenterol Surg. 2018;2:400-405. [PMID: 30460342 DOI: 10.1002/ags3.12199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
47 Inaki N, Etoh T, Ohyama T, Uchiyama K, Katada N, Koeda K, Yoshida K, Takagane A, Kojima K, Sakuramoto S, Shiraishi N, Kitano S. A Multi-institutional, Prospective, Phase II Feasibility Study of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Locally Advanced Gastric Cancer (JLSSG0901). World J Surg. 2015;39:2734-2741. [PMID: 26170158 DOI: 10.1007/s00268-015-3160-z] [Cited by in Crossref: 134] [Cited by in F6Publishing: 124] [Article Influence: 26.8] [Reference Citation Analysis]
48 Knab LM, Belotte J, Munshi HG, Bentrem DJ. Comparative Effectiveness in Esophagogastric Cancer. In: Bilimoria KY, Minami CA, Mahvi DM, editors. Comparative Effectiveness in Surgical Oncology. Cham: Springer International Publishing; 2015. pp. 121-42. [DOI: 10.1007/978-3-319-12553-4_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
49 Sanford M. S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations. Drugs. 2013;73:845-855. [PMID: 23719766 DOI: 10.1007/s40265-013-0062-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
50 Han JH, Kim M, Kim HJ, Jang SB, Bae SJ, Lee IK, Ryu D, Ha KT. Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil. Int J Mol Sci 2021;22:5406. [PMID: 34065602 DOI: 10.3390/ijms22105406] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Abadir A, Streutker C, Brezden-Masley C, Grin A, Kim YI. Intestinal metaplasia and the risk of gastric cancer in an immigrant asian population. Clin Med Insights Gastroenterol 2012;5:43-50. [PMID: 24833933 DOI: 10.4137/CGast.S10070] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
52 Lordick F. To resect or not resect in metastatic gastric cancer: that is the question! Gastric Cancer 2012;15:229-31. [PMID: 22282136 DOI: 10.1007/s10120-011-0136-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
53 Wu Y, Wei ZW, He YL, Schwarz RE, Smith DD, Xia GK, Zhang CH. Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol 2013; 19(21): 3309-3315 [PMID: 23745033 DOI: 10.3748/wjg.v19.i21.3309] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
54 Foo M, Crosby T, Rackley T, Leong T. Role of (chemo)-radiotherapy in resectable gastric cancer. Clin Oncol (R Coll Radiol). 2014;26:541-550. [PMID: 24996375 DOI: 10.1016/j.clon.2014.06.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
55 Rivera F, Grávalos C, García-Carbonero R. SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clin Transl Oncol. 2012;14:528-535. [PMID: 22721798 DOI: 10.1007/s12094-012-0836-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
56 Yoshikawa T, Aoyama T, Sakamaki K, Oshima T, Lin J, Zhang S, Sapari NS, Soong R, Tan I, Chan XB, Bottomley D, Hewitt LC, Arai T, Teh BT, Epstein D, Ogata T, Kameda Y, Miyagi Y, Tsuburaya A, Morita S, Grabsch HI, Tan P. Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer. J Cancer 2019;10:5130-8. [PMID: 31602266 DOI: 10.7150/jca.34741] [Reference Citation Analysis]
57 Borgstein ABJ, van Berge Henegouwen MI, Lameris W, Eshuis WJ, Gisbertz SS; Dutch Upper GI Cancer Audit. Staging laparoscopy in gastric cancer surgery. A population-based cohort study in patients undergoing gastrectomy with curative intent. Eur J Surg Oncol 2021;47:1441-8. [PMID: 33234483 DOI: 10.1016/j.ejso.2020.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
58 Montori G, Coccolini F, Ceresoli M, Catena F, Colaianni N, Poletti E, Ansaloni L. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol. 2014;2014:912418. [PMID: 24693422 DOI: 10.1155/2014/ 912418] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
59 Batista TP, Martins MR. Lymph node dissection for gastric cancer: a critical review. Oncol Rev 2012;6:e12. [PMID: 25992202 DOI: 10.4081/oncol.2012.e12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
60 Imamura H, Kurokawa Y, Tsujinaka T, Inoue K, Kimura Y, Iijima S, Shimokawa T, Furukawa H. Intraoperative versus extended antimicrobial prophylaxis after gastric cancer surgery: a phase 3, open-label, randomised controlled, non-inferiority trial. Lancet Infect Dis. 2012;12:381-387. [PMID: 22297080 DOI: 10.1016/s1473-3099(11)70370-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
61 Bernards N, Creemers GJ, Nieuwenhuijzen GA, Bosscha K, Pruijt JF, Lemmens VE. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol. 2013;24:3056-3060. [PMID: 24121120 DOI: 10.1093/annonc/mdt401] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
62 Kim IH, Park SS, Lee CM, Kim MC, Kwon IK, Min JS, Kim HI, Lee HH, Lee SI, Chae H. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study. Ann Surg Oncol. 2018;25:1176-1183. [PMID: 29450755 DOI: 10.1245/s10434-018-6375-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
63 Coupe NA, Karikios D, Chong S, Yap J, Ng W, Merrett N, Lin M. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Ann Nucl Med. 2014;28:128-135. [PMID: 24297388 DOI: 10.1007/s12149-013-0791-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
64 Schima W, Kölblinger C, Ba-Ssalamah A. Non-invasive diagnosis of focal liver lesions: an individualized approach. Cancer Imaging 2012;12:365-72. [PMID: 23023267 DOI: 10.1102/1470-7330.2012.9025] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
65 Tourani SS, Cabalag C, Link E, Chan ST, Duong CP. Laparoscopy and peritoneal cytology: important prognostic tools to guide treatment selection in gastric adenocarcinoma. ANZ J Surg. 2015;85:69-73. [PMID: 23647832 DOI: 10.1111/ans.12197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
66 Luo Y, Gao P, Song Y, Sun J, Huang X, Zhao J, Ma B, Li Y, Wang Z. Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis. World J Surg Oncol. 2016;14:49. [PMID: 26912240 DOI: 10.1186/s12957-016-0805-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
67 Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, Hölscher AH, Lordick F, Malfertheiner P, Messmann H, Meyer H, Palmqvist A, Röcken C, Schuhmacher C, Stahl M, Stuschke M, Vieth M, Wittekind C, Wagner D, Mönig SP. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 2015;18:550-63. [DOI: 10.1007/s10120-014-0403-x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
68 Zhang X, Huang H, Wei Z, Zhu Z, Yang D, Fu H, Xu J, Hu Z, Zhang Y, You Q, Huang X, Yan R, Wang W, Cai Q. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis. Cancer Manag Res 2020;12:6641-53. [PMID: 32801898 DOI: 10.2147/CMAR.S258360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
69 Son SY, Jung DH, Lee CM, Ahn SH, Ahn HS, Park DJ, Kim HH. Laparoscopic gastrectomy versus open gastrectomy for gastric cancer in patients with body mass index of 30 kg/m2 or more. Surg Endosc 2015;29:2126-32. [PMID: 25480601 DOI: 10.1007/s00464-014-3953-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
70 Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach? Crit Rev Oncol Hematol. 2013;88:416-426. [PMID: 23764501 DOI: 10.1016/j.critrevonc.2013.05.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
71 Makarewicz W, Bobowicz M, Dubowik M, Kosinski A, Jastrzebski T, Jaskiewicz J. Endoscopic submucosal dissection of gastric ectopic pancreas. Wideochir Inne Tech Maloinwazyjne 2013;8:249-52. [PMID: 24130642 DOI: 10.5114/wiitm.2011.33709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
72 Xu AM, Huang L, Liu W, Gao S, Han WX, Wei ZJ. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9:e86941. [PMID: 24497999 DOI: 10.1371/journal.pone.0086941] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
73 Bao H, Xu N, Li Z, Ren H, Xia H, Li N, Yu H, Wei J, Jiang C, Liu L. Effect of laparoscopic gastrectomy on compliance with adjuvant chemotherapy in patients with gastric cancer. Medicine (Baltimore) 2017;96:e6839. [PMID: 28538373 DOI: 10.1097/MD.0000000000006839] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Szczepanik AM, Paszko A, Szura M, Scully-Horner T, Kulig J. Alternative staging of regional lymph nodes in gastric cancer. Prz Gastroenterol 2016;11:145-9. [PMID: 27713774 DOI: 10.5114/pg.2016.61492] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
75 Yoshikawa T, Morita S, Tanabe K, Nishikawa K, Ito Y, Matsui T, Fujitani K, Kimura Y, Fujita J, Aoyama T, Hayashi T, Cho H, Tsuburaya A, Miyashita Y, Sakamoto J. Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. Eur J Cancer. 2016;62:103-111. [PMID: 27244537 DOI: 10.1016/j.ejca.2016.04.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
76 Xu W, Wang L, Yan C, He C, Lu S, Ni Z, Hua Z, Zhu Z, Sah BK, Yang Z, Zheng Y, Feng R, Li C, Yao X, Chen M, Liu W, Yan M, Zhu Z. Neoadjuvant Chemotherapy Versus Direct Surgery for Locally Advanced Gastric Cancer With Serosal Invasion (cT4NxM0): A Propensity Score-Matched Analysis. Front Oncol 2021;11:718556. [PMID: 34497768 DOI: 10.3389/fonc.2021.718556] [Reference Citation Analysis]
77 Le Roux PY, Duong CP, Cabalag CS, Parameswaran BK, Callahan J, Hicks RJ. Incremental diagnostic utility of gastric distension FDG PET/CT. Eur J Nucl Med Mol Imaging 2016;43:644-53. [PMID: 26487512 DOI: 10.1007/s00259-015-3211-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
78 Zhong Q, Chen QY, Parisi A, Ma YB, Lin GT, Desiderio J, Yan S, Xie JW, Wang JB, Hou JF, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Liu ZY, Que SJ, Li P, Zheng CH, Huang CM. Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study. Oncologist 2021;26:e99-e110. [PMID: 32864840 DOI: 10.1634/theoncologist.2020-0022] [Reference Citation Analysis]
79 Wang XQ, Zheng Y, Fang PF, Song XB. Nesfatin-1 is a potential diagnostic biomarker for gastric cancer. Oncol Lett 2020;19:1577-83. [PMID: 31966083 DOI: 10.3892/ol.2019.11200] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Hanna GB, Amygdalos I, Ni M, Boshier PR, Mikhail S, Lloyd J, Goldin R. Improving the standard of lymph node retrieval after gastric cancer surgery. Histopathology 2013;63:316-24. [PMID: 23837447 DOI: 10.1111/his.12167] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
81 Elzouki AN, Buhjab SI, Alkialani A, Habel S, Sasco AJ. Gastric cancer and Helicobacter pylori infection in the eastern Libya: a descriptive epidemiological study. Arab J Gastroenterol. 2012;13:85-88. [PMID: 22980598 DOI: 10.1016/j.ajg.2012.06.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
82 McQuade RM, Stojanovska V, Abalo R, Bornstein JC, Nurgali K. Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Front Pharmacol 2016;7:414. [PMID: 27857691 DOI: 10.3389/fphar.2016.00414] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 13.6] [Reference Citation Analysis]
83 Vadthya G, Ramakrishnaiah VPN, Krishnamachari S. Short-Term Outcome in Patients Undergoing Gastrectomy with D2 Lymphadenectomy for Carcinoma Stomach. Indian J Surg Oncol 2017;8:304-11. [DOI: 10.1007/s13193-017-0620-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
84 Bang Y. Capecitabine in gastric cancer. Expert Review of Anticancer Therapy 2014;11:1791-806. [DOI: 10.1586/era.11.172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
85 Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: A 2014 update. World J Gastroenterol 2014; 20(38): 13637-13647 [PMID: 25320502 DOI: 10.3748/wjg.v20.i38.13637] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
86 Yeh JM, Tramontano AC, Hur C, Schrag D. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. Gastric Cancer 2017;20:811-24. [PMID: 28205057 DOI: 10.1007/s10120-017-0693-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
87 Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, Hirabayashi N, Mikata S, Iwahashi M, Fukushima R, Takiguchi N, Miyashiro I, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol. 2014;21:213-219. [PMID: 23838904 DOI: 10.1245/s10434-013-3055-x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
88 Russo A, Li P, Strong VE. Differences in the multimodal treatment of gastric cancer: East versus west. J Surg Oncol 2017;115:603-14. [PMID: 28181265 DOI: 10.1002/jso.24517] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 8.5] [Reference Citation Analysis]
89 Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15:146-151. [PMID: 23355076 DOI: 10.1007/s11912-013-0298-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
90 Peixoto RD, Lim HJ, Kim H, Abdullah A, Cheung WY. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer 2014;45:325-33. [PMID: 24756830 DOI: 10.1007/s12029-014-9601-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
91 Kanda M, Murotani K, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis. Surgery. 2015;158:1573-1580. [PMID: 26120068 DOI: 10.1016/j.surg.2015.05.017] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 6.0] [Reference Citation Analysis]
92 Son SY, Kong SH, Ahn HS, Park YS, Ahn SH, Suh YS, Park DJ, Lee HJ, Kim HH, Yang HK. The value of N staging with the positive lymph node ratio, and splenectomy, for remnant gastric cancer: A multicenter retrospective study. J Surg Oncol. 2017;116:884-893. [PMID: 28650587 DOI: 10.1002/jso.24737] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
93 Kim JS, Kang SH, Moon HS, Lee ES, Kim SH, Sung JK, Lee BS, Jeong HY. Clinical outcome after endoscopic submucosal dissection for early gastric cancer of absolute and expanded indication. Medicine (Baltimore) 2017;96:e6710. [PMID: 28445280 DOI: 10.1097/MD.0000000000006710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
94 Grunnet M, Mau-Sørensen M, Brünner N. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol 2013;48:899-905. [PMID: 23834019 DOI: 10.3109/00365521.2013.812235] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
95 Giacopuzzi S, Bencivenga M, Cipollari C, Weindelmayer J, de Manzoni G. Lymphadenectomy: how to do it? Transl Gastroenterol Hepatol 2017;2:28. [PMID: 28447063 DOI: 10.21037/tgh.2017.03.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
96 Groene O, Crosby T, Hardwick RH, Riley S, Greenaway K, Cromwell D. A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer. BMJ Open 2015;5:e006724. [PMID: 25740023 DOI: 10.1136/bmjopen-2014-006724] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
97 Wang H, Qi H, Liu X, Gao Z, Hidasa I, Aikebaier A, Li K. Positive lymph node ratio is an index in predicting prognosis for remnant gastric cancer with insufficient retrieved lymph node in R0 resection. Sci Rep 2021;11:2022. [PMID: 33479327 DOI: 10.1038/s41598-021-81663-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Kim HI, Hur H, Kim YN, Lee HJ, Kim MC, Han SU, Hyung WJ. Standardization of D2 lymphadenectomy and surgical quality control (KLASS-02-QC): a prospective, observational, multicenter study [NCT01283893]. BMC Cancer. 2014;14:209. [PMID: 24646327 DOI: 10.1186/1471-2407-14-209] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 6.4] [Reference Citation Analysis]
99 Fujikawa H, Yoshikawa T, Hasegawa S, Hayashi T, Aoyama T, Ogata T, Cho H, Oshima T, Rino Y, Morita S, Masuda M. Diagnostic value of computed tomography for staging of clinical T1 gastric cancer. Ann Surg Oncol. 2014;21:3002-3007. [PMID: 24687153 DOI: 10.1245/s10434-014-3667-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
100 Brar S, Law C, McLeod R, Helyer L, Swallow C, Paszat L, Seevaratnam R, Cardoso R, Dixon M, Mahar A. Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg. 2013;217:347-57.e1. [PMID: 23664139 DOI: 10.1016/j.jamcollsurg.2013.01.067] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
101 Bystricky B, Chau I. Patupilone in cancer treatment. Expert Opin Investig Drugs 2011;20:107-17. [PMID: 21142807 DOI: 10.1517/13543784.2011.542148] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
102 Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y. Integrated multigene expression panel to prognosticate patients with gastric cancer. Oncotarget 2018;9:18775-85. [PMID: 29721160 DOI: 10.18632/oncotarget.24661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
103 Shen L, Shan YS, Hu HM, Price TJ, Sirohi B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, Park SR, Fujii M, Kang YK, Chen LT. Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013;14:e535-e547. [PMID: 24176572 DOI: 10.1016/s1470-2045(13)70436-4] [Cited by in Crossref: 294] [Cited by in F6Publishing: 185] [Article Influence: 36.8] [Reference Citation Analysis]
104 Goodman MD, McPartland S, Detelich D, Saif MW. Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.J Gastrointest Oncol. 2016;7:45-57. [PMID: 26941983 DOI: 10.3978/j.issn.2078-6891.2015.111] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
105 Kanda M, Kobayashi D, Tanaka C, Iwata N, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Murotani K, Fujiwara M, Kodera Y. Adverse prognostic impact of perioperative allogeneic transfusion on patients with stage II/III gastric cancer. Gastric Cancer. 2016;19:255-263. [PMID: 25563579 DOI: 10.1007/s10120-014-0456-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 8.2] [Reference Citation Analysis]
106 Toiyama Y, Yasuda H, Ohi M, Yoshiyama S, Araki T, Tanaka K, Inoue Y, Mohri Y, Kusunoki M. Clinical impact of preoperative albumin to globulin ratio in gastric cancer patients with curative intent. The American Journal of Surgery 2017;213:120-6. [DOI: 10.1016/j.amjsurg.2016.05.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
107 Aoyama T, Hutchins G, Arai T, Sakamaki K, Miyagi Y, Tsuburaya A, Ogata T, Oshima T, Earle S, Yoshikawa T, Grabsch HI. Identification of a high-risk subtype of intestinal-type Japanese gastric cancer by quantitative measurement of the luminal tumor proportion. Cancer Med 2018;7:4914-23. [PMID: 30160049 DOI: 10.1002/cam4.1744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
108 Jürgensen C, Brand J, Nothnagel M, Arlt A, Neser F, Habeck JO, Schreiber S, Stölzel U, Zeitz M, Hampe J. Prognostic relevance of gastric cancer staging by endoscopic ultrasound. Surg Endosc. 2013;27:1124-1129. [PMID: 23052533 DOI: 10.1007/s00464-012-2558-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
109 Yoon HJ, Kim YH, Kim JH, Kim H, Kim H, Park JJ, Youn YH, Park H, Kim JW, Hyung WJ, Noh SH, Choi SH. Are new criteria for mixed histology necessary for endoscopic resection in early gastric cancer? Pathol Res Pract. 2016;212:410-414. [PMID: 26907784 DOI: 10.1016/j.prp.2016.02.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
110 Eatock MM, Tebbutt NC, Bampton CL, Strickland AH, Valladares-Ayerbes M, Swieboda-Sadlej A, Van Cutsem E, Nanayakkara N, Sun YN, Zhong ZD, Bass MB, Adewoye AH, Bodoky G. Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Ann Oncol 2013;24:710-8. [PMID: 23108953 DOI: 10.1093/annonc/mds502] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
111 Fenn MB, Xanthopoulos P, Pyrgiotakis G, Grobmyer SR, Pardalos PM, Hench LL. Raman Spectroscopy for Clinical Oncology. Advances in Optical Technologies 2011;2011:1-20. [DOI: 10.1155/2011/213783] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
112 Shim CN, Lee SK. Endoscopic submucosal dissection for undifferentiated-type early gastric cancer: do we have enough data to support this? World J Gastroenterol. 2014;20:3938-3949. [PMID: 24744583 DOI: 10.3748/wjg.v20.i14.393] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
113 Kurtz J, Dufour P. Evolving standards of care in advanced gastric cancer. Future Oncology 2011;7:1441-50. [DOI: 10.2217/fon.11.115] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
114 Kawakami H, Okamoto I. MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer. 2016;19:687-695. [PMID: 26690587 DOI: 10.1007/s10120-015-0585-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
115 Antonakis PT, Ashrafian H, Isla AM. Laparoscopic gastric surgery for cancer: Where do we stand? World J Gastroenterol 2014; 20(39): 14280-14291 [PMID: 25339815 DOI: 10.3748/wjg.v20.i39.14280] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
116 Bencivenga M, Verlato G, Mengardo V, Weindelmayer J, Allum WH. Do all the European surgeons perform the same D2? The need of D2 audit in Europe. Updates Surg 2018;70:189-95. [PMID: 29869322 DOI: 10.1007/s13304-018-0542-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
117 Park JC, Lee YK, Kim SY, Roh Y, Hahn KY, Shin SK, Lee SK, Lee YC, Kim HI, Cheong JH, Hyung WJ, Noh SH. Long-term outcomes of endoscopic submucosal dissection in comparison to surgery in undifferentiated-type intramucosal gastric cancer using propensity score analysis. Surg Endosc. 2018;32:2046-2057. [PMID: 29052072 DOI: 10.1007/s00464-017-5901-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
118 Polom K, Marano L, Roviello G, Petrioli R, Piagnerelli R, de Franco L, Marrelli D, Roviello F. Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence. International Journal of Hyperthermia 2015;32:173-9. [DOI: 10.3109/02656736.2015.1111432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
119 de Steur WO, Hartgrink HH, Dikken JL, Putter H, van de Velde CJ. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. Br J Surg 2015;102:1388-93. [PMID: 26313463 DOI: 10.1002/bjs.9891] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
120 Choi YY, An JY, Katai H, Seto Y, Fukagawa T, Okumura Y, Kim DW, Kim HI, Cheong JH, Hyung WJ, Noh SH. A Lymph Node Staging System for Gastric Cancer: A Hybrid Type Based on Topographic and Numeric Systems. PLoS One 2016;11:e0149555. [PMID: 26967161 DOI: 10.1371/journal.pone.0149555] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
121 Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. JCO 2011;29:4387-93. [DOI: 10.1200/jco.2011.36.5908] [Cited by in Crossref: 746] [Cited by in F6Publishing: 428] [Article Influence: 74.6] [Reference Citation Analysis]
122 Sun M, Si G, Sun HS, Si FC. Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway. Biochem Biophys Res Commun 2018;496:1183-90. [PMID: 29402413 DOI: 10.1016/j.bbrc.2018.01.167] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
123 Lee JW, Lee SM, Son MW, Lee MS. Diagnostic performance of FDG PET/CT for surveillance in asymptomatic gastric cancer patients after curative surgical resection. Eur J Nucl Med Mol Imaging. 2016;43:881-888. [PMID: 26611426 DOI: 10.1007/s00259-015-3249-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
124 Zhou HY, Yi W, Wang J, Zhang J, Wang WJ, Hu ZQ. Association of perioperative allogeneic blood transfusions and prognosis of patients with gastric cancer after curative gastrectomy. Am J Surg 2014;208:80-7. [PMID: 24262934 DOI: 10.1016/j.amjsurg.2013.08.029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
125 He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World J Gastroenterol 2014; 20(1): 264-273 [PMID: 24415881 DOI: 10.3748/wjg.v20.i1.264] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
126 Goto H, Yasuda T, Oshikiri T, Kanaji S, Kawasaki K, Imanishi T, Oyama M, Kakinoki K, Ohara T, Sendo H, Fujino Y, Tominaga M, Kakeji Y. Comparing the short-term outcomes of laparoscopic distal gastrectomy with D1+ and D2 lymph node dissection for gastric cancer: LDG with D1 and D2 lymph node dissection. Asian J Endosc Surg 2016;9:116-21. [DOI: 10.1111/ases.12269] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
127 Choi ES, Kim H, Kim HP, Choi Y, Goh SH. CD44v8-10 as a potential theranostic biomarker for targeting disseminated cancer cells in advanced gastric cancer. Sci Rep 2017;7:4930. [PMID: 28694503 DOI: 10.1038/s41598-017-05247-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
128 Brown J, Liepa AM, Bapat B, Madhwani S, Lorenzen S, García-Foncillas J, Candrilli SD, Kaye JA. Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom. Eur J Cancer Care (Engl) 2020;29:e13213. [PMID: 31883156 DOI: 10.1111/ecc.13213] [Reference Citation Analysis]
129 Kneissl J, Hartmann A, Pfarr N, Erlmeier F, Lorber T, Keller S, Zwingenberger G, Weichert W, Luber B. Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines. J Cancer Res Clin Oncol. 2017;143:573-600. [PMID: 27933395 DOI: 10.1007/s00432-016-2308-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
130 Alshehri A, Alanezi H, Kim BS. Prognosis factors of advanced gastric cancer according to sex and age. World J Clin Cases 2020; 8(9): 1608-1619 [PMID: 32432139 DOI: 10.12998/wjcc.v8.i9.1608] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
131 de Manzoni G, Verlato G, Bencivenga M, Marrelli D, Di Leo A, Giacopuzzi S, Cipollari C, Roviello F. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol. 2015;41:534-540. [PMID: 25707350 DOI: 10.1016/j.ejso.2015.01.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
132 Signal V, Sarfati D, Cunningham R, Gurney J, Koea J, Ellison-Loschmann L. Indigenous inequities in the presentation and management of stomach cancer in New Zealand: a country with universal health care coverage. Gastric Cancer 2015;18:571-9. [PMID: 25098927 DOI: 10.1007/s10120-014-0410-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
133 Aoyama T, Fujikawa H, Cho H, Ogata T, Shirai J, Hayashi T, Rino Y, Masuda M, Oba MS, Morita S. A methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective, randomized, controlled study. Am J Surg Pathol. 2015;39:266-273. [PMID: 25356528 DOI: 10.1097/pas.0000000000000336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
134 Lee JH. Ongoing surgical clinical trials on minimally invasive surgery for gastric cancer: Korea. Transl Gastroenterol Hepatol 2016;1:40. [PMID: 28138607 DOI: 10.21037/tgh.2016.05.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
135 Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 2018;10:239-48. [PMID: 29445300 DOI: 10.2147/CMAR.S149619] [Cited by in Crossref: 339] [Cited by in F6Publishing: 216] [Article Influence: 113.0] [Reference Citation Analysis]
136 Haverkamp L, Brenkman HJ, Ruurda JP, Ten Kate FJ, van Hillegersberg R. The Oncological Value of Omentectomy in Gastrectomy for Cancer. J Gastrointest Surg 2016;20:885-90. [PMID: 26895951 DOI: 10.1007/s11605-016-3092-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
137 Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21. [PMID: 32512697 DOI: 10.3390/ijms21114012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 37.0] [Reference Citation Analysis]
138 Kitagawa Y, Takeuchi H, Takagi Y, Natsugoe S, Terashima M, Murakami N, Fujimura T, Tsujimoto H, Hayashi H, Yoshimizu N, Takagane A, Mohri Y, Nabeshima K, Uenosono Y, Kinami S, Sakamoto J, Morita S, Aikou T, Miwa K, Kitajima M. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. J Clin Oncol. 2013;31:3704-3710. [PMID: 24019550 DOI: 10.1200/jco.2013.50.3789] [Cited by in Crossref: 174] [Cited by in F6Publishing: 116] [Article Influence: 21.8] [Reference Citation Analysis]
139 Shishido Y, Fujitani K, Yamamoto K, Hirao M, Tsujinaka T, Sekimoto M. C-reactive protein on postoperative day 3 as a predictor of infectious complications following gastric cancer resection. Gastric Cancer. 2016;19:293-301. [PMID: 25560875 DOI: 10.1007/s10120-014-0455-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
140 Yang L, Huang X, Wang W, Jiang T, Ding F. XEDAR inhibits the proliferation and induces apoptosis of gastric cancer cells by regulating JNK signaling pathway. Biosci Rep 2019;39:BSR20192726. [PMID: 31829409 DOI: 10.1042/BSR20192726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Naeimi M, Shafiee M, Kermanshahi F, Khorasanchi Z, Khazaei M, Ryzhikov M, Avan A, Gorji N, Hassanian SM. Saffron (Crocus sativus) in the treatment of gastrointestinal cancers: Current findings and potential mechanisms of action. J Cell Biochem 2019;120:16330-9. [PMID: 31245875 DOI: 10.1002/jcb.29126] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
142 Degiuli M, De Manzoni G, Di Leo A, D’Ugo D, Galasso E, Marrelli D, Petrioli R, Polom K, Roviello F, Santullo F, Morino M. Gastric cancer: Current status of lymph node dissection. World J Gastroenterol 2016; 22(10): 2875-2893 [PMID: 26973384 DOI: 10.3748/wjg.v22.i10.2875] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 49] [Article Influence: 11.4] [Reference Citation Analysis]
143 Gomez-Martín C, Lopez-Rios F, Aparicio J, Barriuso J, García-Carbonero R, Pazo R, Rivera F, Salgado M, Salud A, Vázquez-Sequeiros E, Lordick F. A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond. Cancer Lett 2014;351:30-40. [PMID: 24943493 DOI: 10.1016/j.canlet.2014.05.019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
144 Titov SE, Anishchenko VV, Poloz TL, Veryaskina YA, Arkhipova AA, Ustinov SN. [Differential diagnostics of gastric cancer and precancerous changes of the gastric mucosa using analysis of expression of six microRNAS.]. Klin Lab Diagn 2020;65:131-6. [PMID: 32159312 DOI: 10.18821/0869-2084-2020-65-2-131-136] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Lee YJ, Chung YE, Lim JS, Kim JH, Kim YJ, Lee HJ, You JS, Kim MJ, Kim KW. Cumulative radiation exposure during follow-up after curative surgery for gastric cancer. Korean J Radiol 2012;13:144-51. [PMID: 22438681 DOI: 10.3348/kjr.2012.13.2.144] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
146 Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist 2013;18:1013-21. [PMID: 23966224 DOI: 10.1634/theoncologist.2012-0462] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
147 Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT. Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev 2013;39:113-7. [PMID: 23062719 DOI: 10.1016/j.ctrv.2012.09.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
148 Yan B, Ren Z, Sun J, Ding C, Yang D. IGF2-AS knockdown inhibits glycolysis and accelerates apoptosis of gastric cancer cells through targeting miR-195/CREB1 axis. Biomed Pharmacother 2020;130:110600. [PMID: 34321174 DOI: 10.1016/j.biopha.2020.110600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Zeng X, Shi H, Wang J, Cui S, Tang H, Zhang X. Long noncoding RNA aberrant expression profiles after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of AGC ascertained by microarray analysis. Tumour Biol. 2015;36:5021-5029. [PMID: 25652469 DOI: 10.1007/s13277-015-3153-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
150 Lu J, Huang C, Zheng C, Li P, Xie J, Wang J, Lin J, Chen Q, Cao L, Lin M. Major perioperative complications in laparoscopic spleen-preserving total gastrectomy for gastric cancer: perspectives from a high-volume center. Surg Endosc 2016;30:1034-42. [DOI: 10.1007/s00464-015-4291-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
151 Lee HW, Kim K. Acquisition of histologic diversity contributes to not only invasiveness but also lymph node metastasis in early gastric cancer. Pathol Res Pract 2017;213:1023-8. [PMID: 28864348 DOI: 10.1016/j.prp.2017.08.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 Kim JH. Important considerations when contemplating endoscopic resection of undifferentiated-type early gastric cancer. World J Gastroenterol 2016; 22(3): 1172-1178 [PMID: 26811655 DOI: 10.3748/wjg.v22.i3.1172] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
153 Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, Solej M, Degiuli M. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World J Gastroenterol 2018; 24(2): 274-289 [PMID: 29375213 DOI: 10.3748/wjg.v24.i2.274] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 25] [Article Influence: 12.7] [Reference Citation Analysis]
154 Bauer K, Schroeder M, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10-18. [PMID: 25861518 DOI: 10.5230/jgc.2015.15.1.10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
155 Eom BW, Joo J, Kim YW, Reim D, Park JY, Yoon HM, Ryu KW, Lee JY, Kook MC. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery. 2014;155:408-416. [PMID: 24287148 DOI: 10.1016/j.surg.2013.08.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
156 Chevallay M, Jung M, Berlth F, Seung-Hun C, Morel P, Mönig S. Laparoscopic Surgery for Gastric Cancer: The European Point of View. J Oncol 2019;2019:8738502. [PMID: 31214260 DOI: 10.1155/2019/8738502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
157 Chan DL, Cheung M, Earle CC, Coburn N, Mittmann N, Rahman F, Liu N, Singh S. Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. J Gastrointest Cancer 2020;51:189-95. [PMID: 30972631 DOI: 10.1007/s12029-019-00235-8] [Reference Citation Analysis]
158 Becker K, Reim D, Novotny A, Zum Büschenfelde CM, Engel J, Friess H, Höfler H, Langer R. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg. 2012;256:1002-1007. [PMID: 22968067 DOI: 10.1097/sla.0b013e318262a591] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
159 Aoyama T, Yoshikawa T, Miyagi Y, Kameda Y, Shirai J, Hayashi T, Cho H, Oshima T, Yukawa N, Rino Y, Masuda M, Tsuburaya A. Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. Surg Today 2013;43:1390-7. [PMID: 23512532 DOI: 10.1007/s00595-013-0544-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
160 Kalinka-Warzocha E, Plazas JG, Mineur L, Salek T, Hendlisz A, DeCosta L, Vogl FD, Passalacqua R. Chemotherapy treatment patterns and neutropenia management in gastric cancer. Gastric Cancer 2015;18:360-7. [PMID: 24792482 DOI: 10.1007/s10120-014-0375-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
161 Sasako M. Gastric cancer eastern experience. Surg Oncol Clin N Am. 2012;21:71-77. [PMID: 22098832 DOI: 10.1016/j.soc.2011.09.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
162 Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015; 7(8): 102-110 [PMID: 26306142 DOI: 10.4251/wjgo.v7.i8.102] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
163 Cho I, Kwon IG, Guner A, Son T, Kim HI, Kang DR, Noh SH, Lim JS, Hyung WJ. Consideration of clinicopathologic features improves patient stratification for multimodal treatment of gastric cancer.Oncotarget. 2017;8:79594-79603. [PMID: 29108339 DOI: 10.18632/oncotarget.18607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
164 Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Rowsell C, Coburn NG. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15 Suppl 1:S27-S37. [PMID: 21809111 DOI: 10.1007/s10120-011-0071-z] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 6.8] [Reference Citation Analysis]
165 Dikken JL, Cats A, Verheij M, van de Velde CJ. Randomized trials and quality assurance in gastric cancer surgery: Randomized Trials and Quality Assurance. J Surg Oncol 2013;107:298-305. [DOI: 10.1002/jso.23080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
166 Raigani S, Hardacre JM, Kim J, Ammori JB. Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol. 2014;21:569-574. [PMID: 24165900 DOI: 10.1245/s10434-013-3314-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
167 Son T, Hyung WJ. Laparoscopic gastric cancer surgery: Current evidence and future perspectives. World J Gastroenterol 2016; 22(2): 727-735 [PMID: 26811620 DOI: 10.3748/wjg.v22.i2.727] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 30] [Article Influence: 8.6] [Reference Citation Analysis]
168 Deng W, Wang QW, Zhang XT, Lu M, Li J, Li Y, Gong JF, Zhou J, Lu ZH, Shen L. Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. World J Gastroenterol 2014; 20(12): 3356-3363 [PMID: 24696615 DOI: 10.3748/wjg.v20.i12.3356] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
169 Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget 2014;5:2866-80. [PMID: 24930887 DOI: 10.18632/oncotarget.2003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 6.2] [Reference Citation Analysis]
170 Coburn N, Seevaratnam R, Paszat L, Helyer L, Law C, Swallow C, Cardosa R, Mahar A, Lourenco LG, Dixon M. Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. Ann Surg. 2014;259:102-108. [PMID: 23478525 DOI: 10.1097/sla.0b013e318288dd2b] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 4.9] [Reference Citation Analysis]
171 Bringeland EA, Wasmuth HH, Fougner R, Mjønes P, Grønbech JE. Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery. Br J Surg. 2014;101:1712-1720. [PMID: 25312592 DOI: 10.1002/bjs.9650] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
172 Rosso KJ, Nathanson SD. Techniques that accurately identify the sentinel lymph node in cancer. World J Surg Proced 2015; 5(1): 14-26 [DOI: 10.5412/wjsp.v5.i1.14] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Hayashi T, Aoyama T, Tanabe K, Nishikawa K, Ito Y, Ogata T, Cho H, Morita S, Miyashita Y, Tsuburaya A. Low creatinine clearance is a risk factor for D2 gastrectomy after neoadjuvant chemotherapy. Ann Surg Oncol. 2014;21:3015-3022. [PMID: 24715213 DOI: 10.1245/s10434-014-3670-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
174 Wang P, Xiao F, Gong B, Liu F, Xu H. A Nomogram for Predicting Overall Survival of Gastric Cancer Patients with Insufficient Lymph Nodes Examined. J Gastrointest Surg 2017;21:947-56. [DOI: 10.1007/s11605-017-3401-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
175 Shim CN, Lee SK. Endoscopic submucosal dissection for undifferentiated-type early gastric cancer: Do we have enough data to support this? World J Gastroenterol 2014; 20(14): 3938-3949 [PMID: 24744583 DOI: 10.3748/wjg.v20.i14.3938] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
176 Pernot S, Mitry E, Samalin E, Dahan L, Dalban C, Ychou M, Seitz JF, Turki H, Mazard T, Zaanan A. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer. 2014;17:341-347. [PMID: 23739764 DOI: 10.1007/s10120-013-0266-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
177 Huszno J, Mrochen-Domin I, Zembala-Nożyńska E, Tukiendorf A, Lange D, Nowara E. Mucin secretion activity of gastric cancer as a prognostic factor: a clinicopathological analysis. Contemp Oncol (Pozn) 2012;16:159-64. [PMID: 23788870 DOI: 10.5114/wo.2012.28796] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
178 Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31:3935-3943. [PMID: 24043745 DOI: 10.1200/jco.2012.48.3552] [Cited by in Crossref: 304] [Cited by in F6Publishing: 173] [Article Influence: 38.0] [Reference Citation Analysis]
179 Jiang B, Sun Q, Tong Y, Wang Y, Ma H, Xia X, Zhou Y, Zhang X, Gao F, Shu P. An immune-related gene signature predicts prognosis of gastric cancer. Medicine (Baltimore) 2019;98:e16273. [PMID: 31277152 DOI: 10.1097/MD.0000000000016273] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
180 Bringeland EA, Wasmuth HH, Grønbech JE. Perioperative chemotherapy for resectable gastric cancer – what is the evidence? Scandinavian Journal of Gastroenterology 2017;52:647-53. [DOI: 10.1080/00365521.2017.1293727] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
181 Bang YJ. Adjuvant chemotherapy: an option for Asian patients only? Recent Results Cancer Res 2012;196:291-305. [PMID: 23129381 DOI: 10.1007/978-3-642-31629-6_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
182 Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Huang CM. Safety and prognostic impact of prophylactic laparoscopic superior mesenteric vein (No. 14v) lymph node dissection for lower-third gastric cancer: a propensity score-matched case-control study. Surg Endosc. 2018;32:1495-1505. [PMID: 28916893 DOI: 10.1007/s00464-017-5837-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
183 Pang T, Wang X, Gao J, Chen W, Shen XJ, Nie MM, Luo T, Yin K, Fang G, Wang KX, Xue XC. Fiber-modified hexon-chimeric oncolytic adenovirus targeting cancer associated fibroblasts inhibits tumor growth in gastric carcinoma. Oncotarget 2017;8:76468-78. [PMID: 29100326 DOI: 10.18632/oncotarget.20273] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
184 Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:CD008415. [PMID: 23999923 DOI: 10.1002/14651858.cd008415.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
185 Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389-1396. [PMID: 25439693 DOI: 10.1016/s1470-2045(14)70473-5] [Cited by in Crossref: 451] [Cited by in F6Publishing: 265] [Article Influence: 64.4] [Reference Citation Analysis]
186 Dai Q, Yan H, Wu X, Liu Y, Huang F, Dong X. Effectiveness and safety of adjunctive traditional Chinese medicine therapy for constipation after cancer chemotherapy: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21770. [PMID: 32846805 DOI: 10.1097/MD.0000000000021770] [Reference Citation Analysis]
187 Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer. 2012;48:2941-2953. [PMID: 22921186 DOI: 10.1016/j.ejca.2012.07.029] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 9.3] [Reference Citation Analysis]
188 Aoyama T. Perioperative body composition changes in the multimodal treatment of gastrointestinal cancer. Surg Today 2020;50:217-22. [PMID: 31028458 DOI: 10.1007/s00595-019-01815-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
189 Märkl B, Moldovan AI, Jähnig H, Cacchi C, Spatz H, Anthuber M, Oruzio DV, Kretsinger H, Arnholdt HM. Combination of Ex Vivo Sentinel Lymph Node Mapping and Methylene Blue-Assisted Lymph Node Dissection in Gastric Cancer: A Prospective and Randomized Study. Ann Surg Oncol 2011;18:1860-8. [DOI: 10.1245/s10434-011-1713-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
190 Eom BW, Ryu KW, Nam BH, Park Y, Lee HJ, Kim MC, Cho GS, Kim CY, Ryu SW, Shin DW, Hyung WJ, Lee JH. Survival nomogram for curatively resected Korean gastric cancer patients: multicenter retrospective analysis with external validation. PLoS One 2015;10:e0119671. [PMID: 25723182 DOI: 10.1371/journal.pone.0119671] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
191 Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy vs Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019;10:458-466. [PMID: 30719140 DOI: 10.7150/jca.27335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
192 Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Law C, Coburn NG. A systematic review of the accuracy and indications for diagnostic laparoscopy prior to curative-intent resection of gastric cancer. Gastric Cancer 2012;15 Suppl 1:S38-47. [PMID: 21667136 DOI: 10.1007/s10120-011-0047-z] [Cited by in Crossref: 73] [Cited by in F6Publishing: 64] [Article Influence: 7.3] [Reference Citation Analysis]
193 Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013;20:1575-1583. [PMID: 23076557 DOI: 10.1245/s10434-012-2720-9] [Cited by in Crossref: 171] [Cited by in F6Publishing: 161] [Article Influence: 19.0] [Reference Citation Analysis]
194 Chen QY, Zhong Q, Zhou JF, Qiu XT, Dang XY, Cai LS, Su GQ, Xu DB, Liu ZY, Li P, Guo KQ, Xie JW, Chen QX, Wang JB, Li TW, Lin JX, Lin SM, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Lin W, He QL, Zheng CH, Huang CM. Development and External Validation of Web-Based Models to Predict the Prognosis of Remnant Gastric Cancer after Surgery: A Multicenter Study. J Oncol. 2019;2019:6012826. [PMID: 31093283 DOI: 10.1155/2019/6012826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
195 Kwon HN, Lee H, Park JW, Kim YH, Park S, Kim JJ. Screening for Early Gastric Cancer Using a Noninvasive Urine Metabolomics Approach. Cancers (Basel) 2020;12:E2904. [PMID: 33050308 DOI: 10.3390/cancers12102904] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
196 Wang L, Wang X, Kou H, He H, Lu M, Zhou L, Yang Y. Comparing single oral contrast-enhanced ultrasonography and double contrast-enhanced ultrasonography in the preoperative Borrmann classification of advanced gastric cancer. Oncotarget 2018;9:8716-24. [PMID: 29492230 DOI: 10.18632/oncotarget.23819] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
197 Fukuchi M, Mochiki E, Ishiguro T, Saito K, Naitoh H, Kumagai Y, Ishibashi K, Ishida H. Prognostic Impact of Splenectomy in Patients with Esophagogastric Junction Carcinoma. In Vivo 2018;32:145-9. [PMID: 29275312 DOI: 10.21873/invivo.11217] [Reference Citation Analysis]
198 Sasako M. Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia. Expert Rev Anticancer Ther. 2019;19:939-945. [PMID: 31661989 DOI: 10.1080/14737140.2019.1685877] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
199 Kanda M, Tanaka H, Shimizu D, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hattori N, Suenaga M, Hayashi M, Iwata N, Yamada S, Fujiwara M, Kodera Y. SYT7 acts as a driver of hepatic metastasis formation of gastric cancer cells. Oncogene. 2018;37:5355-5366. [PMID: 29858600 DOI: 10.1038/s41388-018-0335-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
200 Liu HS, Xiao HS. MicroRNAs as potential biomarkers for gastric cancer. World J Gastroenterol 2014; 20(34): 12007-12017 [PMID: 25232237 DOI: 10.3748/wjg.v20.i34.12007] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 74] [Article Influence: 10.0] [Reference Citation Analysis]
201 Miki Y, Tokunaga M, Bando E, Tanizawa Y, Kawamura T, Terashima M. Evaluation of postoperative pancreatic fistula after total gastrectomy with D2 lymphadenectomy by ISGPF classification. J Gastrointest Surg. 2011;15:1969-1976. [PMID: 21833745 DOI: 10.1007/s11605-011-1628-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
202 Morgagni P, Tringali D, La Barba G, Vittimberga G, Ercolani G. Historical assumptions of lymphadenectomy. Transl Gastroenterol Hepatol 2016;1:90. [PMID: 28138655 DOI: 10.21037/tgh.2016.11.06] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Wang HL, Zhou PY, Zhang Y, Liu P. Relationships between abnormal MMP2 expression and prognosis in gastric cancer: a meta-analysis of cohort studies. Cancer Biother Radiopharm 2014;29:166-72. [PMID: 24784911 DOI: 10.1089/cbr.2014.1608] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]